Results 101 to 110 of about 134,252 (360)

First Report of Homozygous COL7A1 c.5756delG Mutation Causing Recessive Dystrophic Epidermolysis Bullosa in a Non‐Consanguineous Japanese Family

JEADV Clinical Practice, EarlyView.
ABSTRACT Severe recessive dystrophic epidermolysis bullosa (RDEB) is usually caused by biallelic loss‐of‐function mutations in COL7A1. While the c.5756delG variant has been previously reported in heterozygous form, its clinical impact in homozygosity has not been described.
Nozomi Kohama, Sayaka Yamaguchi, Teruki Yanagi, Yumi Akamine, Kimiko Nonaka, Daisuke Utsumi, Kenzo Takahashi   +6 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

PIEZO1 channels in cutaneous free nerve endings: novel insights into itch-scratch-mechanisms

Signal Transduction and Targeted Therapy, 2023
Manuel Pedro Pereira, Henning Wiegmann, Sonja Ständer   +2 more
doaj   +1 more source

MO863: Electronic Patient Reported Outcome (EPRO) Collection in Dopps: Prospective Study Designed to Understand the Severity and Temporal Changes in Pruritus Symptoms in Hemodialysis Patients [PDF]

, 2022
Angelo Karaboyas, Bruce Robinson, Justin M. Albert, Anna Hogan, Lauren Kane, Elham Asgari, Fitsum Guebre‐Egziabher, Piergiorgio Messa, Thomas Weinreich, Sebastian Walpen, Thilo Schaufler, Ronald L. Pisoni   +11 more
openalex   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou, Sharon Edwards, Andrew Affleck   +2 more
wiley   +1 more source

Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. [PDF]

, 2019
BACKGROUND AND OBJECTIVES: To describe the safety and tolerability of intravenous meloxicam compared with placebo across all phase II/III clinical trials.
Bergese, Sergio, Du, Wei, Gan, Tong J., Hobson, Sue, Mack, Randall J., McCallum, Stewart W., Singla, Neil, Viscusi, Eugene R.   +7 more
core   +1 more source

Updated management of malignant biliary tract tumors: an illustrative review [PDF]

, 2016
The management of malignant biliary tumors (MBTs) is complex and requires a multidisciplinary approach. Guidelines and methods of staging for biliary tumors have recently been released by main international societies, altering the clinical and radiologic
Cannavale, Alessandro, Catalano, Carlo, Fanelli, Fabrizio, Fiocca, Fausto, Gazzetti, Marianna, Maher, Ben, Santoni, Mariangela   +6 more
core   +1 more source

Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa

JEADV Clinical Practice, EarlyView.
ABSTRACT Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl ...
Shiho Mori, Manabu Fujimoto, Katsuto Tamai   +2 more
wiley   +1 more source

Human African trypanosomiasis [PDF]

, 2009
Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse flies.
Abel, Agranoff, Ancelle, Ayed, Balasegaram, Balasegaram, Barrett, Barrett, Barrett, Bayer, Bedat-Millet, Bisoffi, Bisser, Bisser, Blum, Blum, Blum, Blum, Blum, Blum, Bronner, Brun, Buguet, Burri, Burri, Chappuis, Chappuis, Chappuis, Chappuis, Chappuis, Chappuis, Checchi, Checchi, Christian Burri, Courtioux, De Raadt, Deborggraeve, Deborggraeve, Dorlo, Doua, Duggan, Dukes, Ekwanzala, Enyaru, Ezzedine, Fevre, Fevre, Francois Chappuis, Greenwood, Gustafsson, Hutchinson, Iborra, Inojosa, Iten, Jamonneau, Jamonneau, Jamonneau, Jamonneau, Jamonneau, Jansson, Jelinek, Johannes Blum, Jordan, Joshi, Kabasa, Kennedy, Kennedy, Koten, Lejon, Lejon, Lejon, Lejon, Lejon, Lejon, Lejon, Lejon, Louis, Lumsden, Lundkvist, Lutumba, Lutumba, Lutumba, Lutumba, MacLean, Macleod, Magnus, Marcello, Marcello, Masocha, Maudlin, Mendonca, Moore, Moore, Moore, Na-Bangchang, Njiokou, Njiru, Noireau, Noireau, Odiit, Odiit, Oscherwitz, Papadopoulos, Paquet, Penchenier, Pepin, Picozzi, Priotto, Priotto, Priotto, Reincke, Reto Brun, Ripamonti, Robays, Robays, Ruiz, Schmid, Shiflett, Simarro, Simarro, Simarro, Simo, Smith, Spencer, Stanghellini, Stevens, Steverding, Steverding, Stijlemans, Stuart, Taylor, Torr, Truc, Truc, Truc, Truc, Van Meirvenne, Van Nieuwenhove, Vanhamme, Vanhollebeke, Vreysen, Welburn, Welburn, Woo   +143 more
core   +2 more sources

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. [PDF]

, 2019
BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited.
Apfelbacher, CJ, Arents, BWM, Barbarot, S, Bosma, AL, Deleuran, M, Eichenfield, LF, Flohr, C, Gerbens, LAA, International TREAT Registry Taskforce, Irvine, AD, Manca, A, Middelkamp-Hup, MA, Schmitt, J, Spuls, PI, Vermeulen, FM, Vestergaard, C, Wall, D, Weidinger, S   +17 more
core